Our Services
Medical Information
Helpful Resources
Published on: 10/5/2026
Prasterone (brand name Intrarosa) is a once-nightly 6.5 mg vaginal insert containing DHEA, a precursor hormone that vaginal cells convert locally into small amounts of estrogen and testosterone to rebuild thinning tissue, restore moisture and elasticity, normalize pH, and ease painful intercourse caused by genitourinary syndrome of menopause. Most users notice improvement within 2 to 12 weeks, with minimal systemic hormone exposure, while the most common side effects are vaginal discharge and application site irritation. Candidacy, cost, how it compares to vaginal estrogen or ospemifene, and cautions for those with a history of breast cancer are important factors to consider, so see below for the complete details before deciding.
Because dryness, burning, irritation, and pain with sex can also stem from infections, skin conditions like lichen sclerosus, pelvic floor dysfunction, or medication side effects, it helps to clarify what is actually driving your symptoms rather than guessing. Take a free, instant, online symptom check to better understand what may be going on and to walk into your next appointment ready to discuss the right treatment options.
Last reviewed for medical accuracy: 10/04/2026
Vaginal dryness is a common symptom of menopause, affecting up to 50% of postmenopausal women. As estrogen levels drop, the tissues of the vulva and vagina can become thinner, less elastic, and less lubricated. This change often leads to discomfort, itching, burning, and pain during intercourse (dyspareunia). One effective, FDA-approved option for local treatment is prasterone, also known as vaginal DHEA. Below, we explain what prasterone is, how it works, its benefits, safety considerations, and practical tips for use.
Prasterone is a precursor hormone. Once it enters vaginal cells, enzymes convert DHEA into:
This local conversion:
Because prasterone acts locally with minimal systemic hormone changes, it targets menopausal dryness without large increases in blood estrogen levels.
Clinical trials and real-world experience show that prasterone can:
Key study outcomes:
Prasterone is intended for:
It is not suitable for women with:
Always review your medical history with a healthcare provider before starting.
Tips for success:
If you don’t experience relief by 12 weeks, discuss alternative options with your healthcare provider.
Prasterone is generally well tolerated. Most side effects are mild and localized:
Because systemic absorption of DHEA is minimal, risks associated with oral hormone therapies—such as blood clots or significant breast tenderness—are very low. However, monitor for:
Do not use vaginal DHEA if you have:
Discuss with your doctor if you have:
While prasterone addresses menopausal vaginal dryness effectively, certain signs warrant prompt medical attention:
For non-urgent concerns, you might start with a free, online symptom check, using the doctor approved Ubie Symptom Checker.
If you experience life-threatening or serious symptoms, please speak to a doctor or visit your nearest emergency department immediately.
Menopausal changes affect more than just your reproductive system. A comprehensive approach can include:
Combining prasterone with these strategies often yields the best comfort and quality of life.
Vaginal DHEA (prasterone) offers a targeted, FDA-approved solution for moderate-to-severe menopausal dryness and dyspareunia. By supplying a local source of DHEA that converts to estrogen and androgen within vaginal cells, it restores tissue health, lubrication, and pH balance without significant systemic hormone exposure. Most women see meaningful relief in 8–12 weeks of daily use.
Key takeaways:
For a free, online symptom check, using the doctor approved Ubie Symptom Checker. And remember, always speak to a doctor about any serious or life-threatening concerns.
By understanding vaginal DHEA and working closely with your healthcare provider, you can reclaim comfort, confidence, and intimacy during menopause.
(References)
* Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18. PMID: 21244215.
* Goel RM, Cappola AR. Dehydroepiandrosterone sulfate and postmenopausal women. Curr Opin Endocrinol Diabetes Obes. 2011 Jun;18(3):171-6. doi: 10.1097/MED.0b013e3283461818. PMID: 21478748.
* Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014 Jul;74(11):1195-207. doi: 10.1007/s40265-014-0259-8. PMID: 25022952.
* Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6. PMID: 26634942.
* Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016 Dec;215(6):704-711. doi: 10.1016/j.ajog.2016.07.045. Epub 2016 Jul 26. PMID: 27472999.
* Seav SM, Dominick SA, Stepanyuk B, Gorman JR, Chingos DT, Ehren JL, Krychman ML, Su HI. Management of sexual dysfunction in breast cancer survivors: a systematic review. Womens Midlife Health. 2015;1:9. doi: 10.1186/s40695-015-0009-4. Epub 2015 Nov 2. PMID: 30766696; PMCID: PMC6297963.
* Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol. 2020 Feb;222(2):103-113. doi: 10.1016/j.ajog.2019.08.043. Epub 2019 Aug 29. PMID: 31473229.
* Marino JM. Genitourinary Syndrome of Menopause. J Midwifery Womens Health. 2021 Nov;66(6):729-739. doi: 10.1111/jmwh.13277. Epub 2021 Aug 31. PMID: 34464022.
* Johnston S, Bouchard C, Fortier M, Wolfman W. Guideline No. 422b: Menopause and Genitourinary Health. J Obstet Gynaecol Can. 2021 Nov;43(11):1301-1307.e1. doi: 10.1016/j.jogc.2021.09.001. Epub 2021 Sep 8. PMID: 34506989.
* Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022 Feb 24;13(2):71-100. doi: 10.5306/wjco.v13.i2.71. PMID: 35316932; PMCID: PMC8894268.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.